News

About this study Primary Objectives: To estimate the percent of participants who achieve a best response of complete response by the end of the PRV combination therapy in the induction therapy phase ...
Adding ibrutinib to rituximab improved outcomes in patients with previously untreated FL who were ineligible for CIT.
Late-onset neutropenia has been reported in lymphoma patients by a number of groups, [7–16] and recent case reports suggest that LON also occurs in rituximab-treated patients with autoimmune ...
Late-onset neutropenia has been reported in lymphoma patients by a number of groups, [7–16] and recent case reports suggest that LON also occurs in rituximab-treated patients with autoimmune disease. ...
Monjuvi in combination with lenalidomide and rituximab significantly improved PFS in patients with relapsed/refractory follicular lymphoma. The Food and Drug Administration (FDA) has approved ...
Sehn LH, Luminari S, Scholz CW, et al. Tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: results from a phase 3 study (inMIND).
CHICAGO — In this video, Ian W. Flinn, MD, PhD, discusses the phase 2 MorningSun study evaluating fixed-duration subcutaneous mosunetuzumab in patients with previously untreated, high-tumor ...
The US Food and Drug Administration (FDA) has approved Monjuvi (tafasitamab-cxix) for use in combination with lenalidomide and rituximab to treat adults with relapsed or refractory follicular ...
Christina Poh, MD, assistant professor, University of Washington, Fred Hutchinson Cancer Center, discusses the recent FDA approval of tafasitamab -cxix (Monjuvi) plus lenalidomide (Revlimid) and ...
The company noted that patients with relapsed or refractory follicular lymphoma achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and ...
The US Food and Drug Administration has approved tafasitamab (Monjuvi, Incyte Corporation) with lenalidomide and rituximab for adults with relapsed or refractory (r/r) follicular lymphoma (FL ...